Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

BioNTech

Fosun Pharma, CanSino take different paths as Covid lift fade

The pair of companies that got strong shots from different Covid vaccines are telling different stories in their latest quarterly results as the pandemic draws down Key Takeaways: Fosun Pharma’s…
May 9, 2023
2196.HK 6185.HK

CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough

Drugmaker CSPC Pharma gets the green light to produce China’s first homegrown mRNA vaccine, but the breakthrough comes too late in the pandemic to impress investors Key Takeaways: News of…
March 29, 2023
1093.HK

Fosun Pharma Sells Down BioNTech Stake, Though Divorce Looks Unlikely

The Chinese company profited handsomely from its investment in the German vaccine maker, and is most likely selling the stake to help service its parent’s large debtKey Takeaways:Fosun Pharma said…
November 15, 2022

FAST NEWS: Fosun Pharma Raises $660 Million in Non-public Placement of A-Shares

The latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) announced on Wednesday it plans to raise up to 4.48 billion yuan ($660 million) through a non-public offering of about…
July 21, 2022

CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

The company’s Convidecia has received emergency-use authorization from the World Health Organization, becoming the third Chinese vaccine to get that nod Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted…
May 26, 2022

AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt

Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
April 18, 2022
B.US

Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins

Company licensed to sell BioNTech’s mRNA vaccine in China reported its revenue rose 28.8% last year, with the Comirnaty vaccine bringing in over $157 million Key takeaways: Fosun Pharma’s revenue…
March 28, 2022
Load more

Recent Articles

May 9, 2023

Fosun Pharma, CanSino take different paths as Covid lift fade

2196.HK 6185.HK
March 29, 2023

CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough

1093.HK
November 15, 2022

Fosun Pharma Sells Down BioNTech Stake, Though Divorce Looks Unlikely

July 21, 2022

FAST NEWS: Fosun Pharma Raises $660 Million in Non-public Placement of A-Shares

May 26, 2022

CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

April 18, 2022

AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt

B.US
March 28, 2022

Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins

RELATED ARTICLES

  1. Clover Biopharmaceuticals Ltd. faces a potentially damaging fight
    April 3, 2025
    Dispute over Covid vaccines casts doubt on Clover Bio recovery
    2197.HK
  2. January 8, 2025
    Fosun moves on from debt crisis with renewed focus on tourism, healthcare
    0656.HK
  3. December 20, 2024
    Fosun Tourism travels back to home base with delisting plan
    1992.HK 0656.HK
  4. March 25, 2025
    Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  5. January 20, 2025
    Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
    ZYBT.US
  6. January 16, 2025
    WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Premium Content
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2024 Bamboo Works. All rights reserved.